The Egyptian Heart Journal (May 2025)

Small interfering RNA effect on lipoprotein(a): a systematic review

  • Omar Almaadawy,
  • Mohamed Mar’ey Hesn,
  • Yomna Ayman Elsalamony,
  • Omar Ayman Abobakr,
  • Abdelrahman Hossam Elshimy,
  • Khaled Alsayed Abulkhair,
  • Mahmoud Mohamed Negm,
  • Ahmed Yasser Shaban,
  • Yakubu Bene-Alhasan,
  • Frank Annie,
  • Adam Belcher,
  • Ahmed Ramy Elashery

DOI
https://doi.org/10.1186/s43044-025-00635-1
Journal volume & issue
Vol. 77, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Background This systematic review investigates the effect of small interfering RNA (siRNA) therapies on lipoprotein(a) [Lp(a)] levels. The purpose is to evaluate the outcomes of recent randomized controlled trials (RCTs) involving siRNA treatments aimed at lowering Lp(a) levels, a known cardiovascular risk factor. Methods A comprehensive search across multiple databases was conducted, identifying 20 published and ongoing RCTs that examined the effects of siRNA therapies such as inclisiran, olpasiran, and SLN360 on Lp(a) levels. The included studies were analyzed to assess Lp(a) reductions and other lipid-related outcomes. Results The RCTs demonstrated significant reductions in Lp(a) levels following siRNA therapy. Additional reductions were noted in LDL-c and apolipoprotein B levels. Side effects were typically mild, including injection site reactions. Conclusions siRNA therapies show promise in effectively lowering Lp(a) levels, with minimal adverse effects. However, further research is required to establish their long-term safety and efficacy.

Keywords